Related Experiment Video
Updated: Jan 16, 2026
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
[Update on allogeneic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus disease]
1Osaka Women's and Children's Hospital Hematology/Oncology.
Insights
Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is a serious T/NK-cell lymphoproliferative disorder. Early treatment, including chemotherapy and stem cell transplantation, is crucial for survival, with HSCT offering the only cure.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is a severe T/NK-cell lymphoproliferative disorder.
- CAEBV presents as a chronic, progressive condition with a high mortality rate if untreated.
- Current management relies on symptomatic relief, multi-step treatments, and supportive care.
Purpose of the Study:
- To outline the standard treatment protocol for CAEBV.
- To highlight the critical role of allogeneic hematopoietic stem cell transplantation (HSCT) as the sole curative option.
- To emphasize the need for timely and aggressive treatment initiation.
Main Methods:
- The study reviews the established three-step treatment approach for CAEBV.
- It incorporates recent advancements in drug development for each treatment phase.
- Analysis of retrospective HSCT data to optimize transplantation outcomes.
Main Results:
- Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only definitive curative treatment for CAEBV.
- Newer therapeutic agents are emerging for the initial treatment steps.
- Retrospective analyses are guiding improvements in HSCT protocols.
Conclusions:
- Prompt diagnosis and initiation of the multi-step treatment are vital for managing CAEBV.
- While supportive and chemotherapeutic measures are important, HSCT is essential for long-term survival.
- Ongoing research and analysis of HSCT outcomes are crucial for advancing CAEBV treatment.
Abstract:
Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is the prototype of EBV-associated T/NK-cell lymphoproliferative diseases (LPDs). CAEBV is a chronic/progressive LPD with a high mortality rate if left untreated with only symptomatic measures. The basic treatment consists of three steps: (1) cooling with steroids, (2) multi-drug combination chemotherapy, and (3) allogeneic hematopoietic stem cell transplantation (HSCT). Once CAEBV is diagnosed, the safest approach is to begin an initial treatment as soon as possible and complete the final treatment while there is still time. New drugs and approaches for each of the 3 steps have emerged in recent years, but HSCT remains the only curative treatment. Many retrospective analyses of HSCT have been published, and have contributed to progress in optimizing transplantation.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...